JPRN-UMIN000011460已完成3 期
A phase III study comparing carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L CBDCA/PEM vs DOC Phase III) - CBDCA/PEM vs DOC Phase III (JCOG1210/WJOG7813L CBDCA/PEM vs DOC Phase III)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 430 人开始时间: 2013年8月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 430
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous active double malignancies 2) Infectious disease requiring systemic treatment 3) Fever of 38 degrees centigrade or higher 4) Psychotic disorder 5) Receiving systemic treatment of steroid or immunosuppressant 6) Uncontrolled diabetes mellitus treated with insulin 7) Uncontrolled hypertension 8) Unstable angina or myocardial infarction within the past 6 months 9) Positive for HBs antigen 10) Interstitial pneumonitis or lung fibrosis identified by chest CT 11) A past hypersensitive for polysorbate
研究者
相似试验
暂停
2 期
A phase II study comparing carboplatin plus pemetrexed followed by maintenance pemetrexed with pemetrexed in elderly patients with advanced epidermal growth factor receptor non-squamous non-small-cell lung cancer (LCEN1301)JPRN-UMIN000013387ung Cancer Experts Network (LCEN)76
已完成
2 期
A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin+Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non- Small Cell Lung Cancer with EGFR sensitive mutations LOGIK1302JPRN-UMIN000011174ung Oncology Group in Kyushu, Japan (LOGIK)65
已完成
2 期
A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin+Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non- Small Cell Lung Cancer without EGFR mutationson-Small Cell Lung CancerJPRN-UMIN000011126ung Oncology Group in Kyushu, Japan (LOGIK)120
已完成
2 期
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.on-squamous Non-small-cell Lung CancerJPRN-UMIN000004731Central Japan Lung Study Group27
已完成
2 期
A phase II study of carboplatin plus pemetrexed followed by gefitinib for stage IIIB/IV non-small cell lung cancer with EGFR mutationon-small cell lung cancer with EGFR mutationJPRN-UMIN000003354Kanagawa Cancer Center60